Deals

Kandi Technologies Raises $11M at 14% Discount via FT Global Capital

By |

Kandi Technologies Group Inc (KNDI) announced that it has raised $11,053,440 in a Common Stock transaction. The common stock was sold at $18.24 per share, an approximate 14% discount to the market price ($21.16) of KNDI at deal announcement. A series of 90,900 18-Month Warrants with an exercise price of $22.80 per share (7.75% premium) was issued to the investors in this transaction. FT Global Capital Inc. acted as the exclusive agent on the transaction. Issuer counsel was Mckenna, Long & Aldridge, LLP and Placement Agent counsel was Schiff Hardin.

Deals

SANUWAVE Health Raises $6.2M in Conv Preferred Deal at 26% Discount from RA Capital

By |

SANUWAVE Health Inc. (SNWV) announced that it has raised $6,175,000 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $0.50 per share, an approximate 26.47% discount to the market price ($0.68) of SNWV at deal announcement. Newport Coast Securities acted as the exclusive agent on the transaction. The investors include RA Capital Management. Placement Agent counsel was Sichenzia Ross Friedman Ference, issuer counsel was Smith, Gambrell, & Russel, and investor counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo.

Deals

Alexza Pharmaceuticals Raises $45M in Equity-linked Debt via Secured by Royalties

By |

Alexza Pharmaceuticals, Inc. (ALXA) announced that it has raised $45,000,000 in a Non-Convertible Notes transaction. The securities accrue interest at a rate of 12.25%. A series of 345,661 60-Month Warrants with an exercise price of $0.01 per share (99.8% discount) was issued to the investors in this transaction. Morgan Stanley acted as the exclusive agent on the transaction. The transaction closed on March 19, 2014.

Deals

Oxygen Biotherapeutics Closes $52M CMPO at 10% Discount via Ladenburg, MTS Health

By |

Oxygen Biotherapeutics Inc. (OXBT) announced that it has raised $51,999,998 in a CMPO/Overnight transaction. The common stock was sold at $5.60 per share, an approximate 10% discount to the market price ($6.21) of OXBT at deal announcement. Ladenburg Thalmann & Co., Inc. and MTS Health Partners acted as underwriters on the transaction. Underwriter counsel was Ellenoff Grossman & Schole LLP and issuer counsel was Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP. Note this Placement is subject to customary closing conditions and is expected to close by 03/21/2014.